Genetics and age-related macular degeneration: A practical review for the clinician

Stephen G. Schwartz; Blake M. Hampton; Jaclyn L. Kovach; Milam A. Brantley

doi:10.2147/OPTH.S109723

Genetics and age-related macular degeneration: A practical review for the clinician

Stephen G. Schwartz, Blake M. Hampton, Jaclyn L. Kovach, Milam A. Brantley

Ophthalmology

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Age-related macular degeneration is a complex disease, with both genetic and environmental risk factors interacting in unknown ways. Currently, 52 gene variants within 34 loci have been significantly associated with age-related macular degeneration. Two well-studied major genes are complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2). There exist several commercially available tests that are proposed to stratify patients into high-risk and low-risk groups, as well as predict response to nutritional supplementation. However, at present, the bulk of the available peer-reviewed evidence suggests that genetic testing is more useful as a research tool than for clinical management of patients.

Original language	English (US)
Pages (from-to)	1229-1235
Number of pages	7
Journal	Clinical Ophthalmology
Volume	10
DOIs	https://doi.org/10.2147/OPTH.S109723
State	Published - Jul 4 2016

Keywords

ARMS2
Age-related macular degeneration
Age-related maculopathy susceptibility 2
CFH
Complement factor H
Pharmacogenetics
Vascular endothelial growth factor

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.2147/OPTH.S109723

Cite this

@article{9f1d525786934255b63ddb0f91743ccb,

title = "Genetics and age-related macular degeneration: A practical review for the clinician",

abstract = "Age-related macular degeneration is a complex disease, with both genetic and environmental risk factors interacting in unknown ways. Currently, 52 gene variants within 34 loci have been significantly associated with age-related macular degeneration. Two well-studied major genes are complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2). There exist several commercially available tests that are proposed to stratify patients into high-risk and low-risk groups, as well as predict response to nutritional supplementation. However, at present, the bulk of the available peer-reviewed evidence suggests that genetic testing is more useful as a research tool than for clinical management of patients.",

keywords = "ARMS2, Age-related macular degeneration, Age-related maculopathy susceptibility 2, CFH, Complement factor H, Pharmacogenetics, Vascular endothelial growth factor",

author = "Schwartz, {Stephen G.} and Hampton, {Blake M.} and Kovach, {Jaclyn L.} and Brantley, {Milam A.}",

note = "Publisher Copyright: {\textcopyright} 2016 Schwartz et al.",

year = "2016",

month = jul,

day = "4",

doi = "10.2147/OPTH.S109723",

language = "English (US)",

volume = "10",

pages = "1229--1235",

journal = "Clinical Ophthalmology",

issn = "1177-5467",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Genetics and age-related macular degeneration

T2 - A practical review for the clinician

AU - Schwartz, Stephen G.

AU - Hampton, Blake M.

AU - Kovach, Jaclyn L.

AU - Brantley, Milam A.

PY - 2016/7/4

Y1 - 2016/7/4

N2 - Age-related macular degeneration is a complex disease, with both genetic and environmental risk factors interacting in unknown ways. Currently, 52 gene variants within 34 loci have been significantly associated with age-related macular degeneration. Two well-studied major genes are complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2). There exist several commercially available tests that are proposed to stratify patients into high-risk and low-risk groups, as well as predict response to nutritional supplementation. However, at present, the bulk of the available peer-reviewed evidence suggests that genetic testing is more useful as a research tool than for clinical management of patients.

AB - Age-related macular degeneration is a complex disease, with both genetic and environmental risk factors interacting in unknown ways. Currently, 52 gene variants within 34 loci have been significantly associated with age-related macular degeneration. Two well-studied major genes are complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2). There exist several commercially available tests that are proposed to stratify patients into high-risk and low-risk groups, as well as predict response to nutritional supplementation. However, at present, the bulk of the available peer-reviewed evidence suggests that genetic testing is more useful as a research tool than for clinical management of patients.

KW - ARMS2

KW - Age-related macular degeneration

KW - Age-related maculopathy susceptibility 2

KW - CFH

KW - Complement factor H

KW - Pharmacogenetics

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84980496703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980496703&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S109723

DO - 10.2147/OPTH.S109723

M3 - Review article

AN - SCOPUS:84980496703

VL - 10

SP - 1229

EP - 1235

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -

Genetics and age-related macular degeneration: A practical review for the clinician

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this